Incyte (INCY) Misses Q3 EPS by 14c; Boosts FY15 Jakafi Net Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Incyte Reports 2015 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
November 3, 2015 7:00 AM EST- $161 million of 2015 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 65 percent growth over the same period last year
- Positive results from two pivotal trials of baricitinib to be highlighted at ACR; baricitinib superior to both methotrexate (RA-BEGIN) and to Humira® (adalimumab) (RA-BEAM) in reducing the signs and symptoms of rheumatoid arthritis
- Agreement announced with Merck to expand clinical collaboration to include a pivotal trial of epacadostat plus pembrolizumab in first-line advanced or metastatic melanoma; proof-of-concept data from the ongoing Phase I/II trial to be presented at SITC
... More